Oncolytics Biotech Inc
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal aden… Read more
Oncolytics Biotech Inc (ONCY) - Total Liabilities
Latest total liabilities as of September 2025: $14.94 Million USD
Based on the latest financial reports, Oncolytics Biotech Inc (ONCY) has total liabilities worth $14.94 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Oncolytics Biotech Inc - Total Liabilities Trend (1999–2024)
This chart illustrates how Oncolytics Biotech Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Oncolytics Biotech Inc Competitors by Total Liabilities
The table below lists competitors of Oncolytics Biotech Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
FutureFuel Corp
NYSE:FF
|
USA | $34.37 Million |
|
ECARX Holdings Inc. Class A Ordinary shares
NASDAQ:ECX
|
USA | $6.61 Billion |
|
Globus Spirits Limited
NSE:GLOBUSSPR
|
India | ₹11.42 Billion |
|
Enwei Pharmaceutical Co. Ltd. A
SHE:301331
|
China | CN¥433.11 Million |
|
Bonduelle SCA
F:BDU
|
Germany | €1.38 Billion |
|
Smartoptics Group AS
OL:SMOP
|
Norway | Nkr23.55 Million |
|
Shenzhen Properties & Resources Development Group Ltd
SHE:200011
|
China | HK$13.40 Billion |
|
Mersana Therapeutics Inc
NASDAQ:MRSN
|
USA | $122.22 Million |
Liability Composition Analysis (1999–2024)
This chart breaks down Oncolytics Biotech Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.84 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 129.93 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.99 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Oncolytics Biotech Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Oncolytics Biotech Inc (1999–2024)
The table below shows the annual total liabilities of Oncolytics Biotech Inc from 1999 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $14.20 Million | +26.18% |
| 2023-12-31 | $11.26 Million | +3.92% |
| 2022-12-31 | $10.83 Million | +10.75% |
| 2021-12-31 | $9.78 Million | +1.96% |
| 2020-12-31 | $9.59 Million | -51.47% |
| 2019-12-31 | $19.77 Million | +127.98% |
| 2018-12-31 | $8.67 Million | -12.13% |
| 2017-12-31 | $9.87 Million | +142.50% |
| 2016-12-31 | $4.07 Million | +50.16% |
| 2015-12-31 | $2.71 Million | -19.69% |
| 2014-12-31 | $3.37 Million | -43.85% |
| 2013-12-31 | $6.01 Million | -17.59% |
| 2012-12-31 | $7.29 Million | +12.10% |
| 2011-12-31 | $6.50 Million | +160.10% |
| 2010-12-31 | $2.50 Million | -43.50% |
| 2009-12-31 | $4.43 Million | -2.38% |
| 2008-12-31 | $4.53 Million | +60.71% |
| 2007-12-31 | $2.82 Million | +1.98% |
| 2006-12-31 | $2.77 Million | +50.15% |
| 2005-12-31 | $1.84 Million | +67.61% |
| 2004-12-31 | $1.10 Million | +6.22% |
| 2003-12-31 | $1.03 Million | -26.61% |
| 2002-12-31 | $1.41 Million | -54.78% |
| 2001-12-31 | $3.12 Million | +78.92% |
| 2000-12-31 | $1.74 Million | +638.27% |
| 1999-12-31 | $236.10K | -- |